Fmr LLC Boosts Holdings in Mural Oncology plc (NASDAQ:MURA)

Fmr LLC raised its stake in shares of Mural Oncology plc (NASDAQ:MURA) by 124.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 20,580 shares of the company’s stock after buying an additional 11,423 shares during the period. Fmr LLC’s holdings in Mural Oncology were worth $64,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Rhumbline Advisers acquired a new position in Mural Oncology in the second quarter valued at approximately $34,000. BBR Partners LLC purchased a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $31,000. Acadian Asset Management LLC acquired a new position in shares of Mural Oncology in the 2nd quarter valued at $998,000. Nicollet Investment Management Inc. purchased a new stake in Mural Oncology during the second quarter worth $308,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Mural Oncology during the second quarter valued at $71,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Insider Buying and Selling

In related news, CFO Adam D. Cutler sold 7,421 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total transaction of $25,305.61. Following the completion of the sale, the chief financial officer now directly owns 71,438 shares in the company, valued at approximately $243,603.58. The trade was a 9.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Mural Oncology Stock Down 1.5 %

MURA opened at $3.24 on Wednesday. The firm’s fifty day simple moving average is $3.60 and its two-hundred day simple moving average is $3.38. Mural Oncology plc has a 52-week low of $2.87 and a 52-week high of $6.25. The company has a market cap of $55.14 million and a price-to-earnings ratio of -0.35.

Analyst Upgrades and Downgrades

MURA has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th. Raymond James started coverage on Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target for the company.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.